| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 67.123 | 135.980 | 162.540 | 171.412 |
| Total Income - EUR | - | - | - | - | - | - | 67.123 | 136.220 | 162.745 | 171.611 |
| Total Expenses - EUR | - | - | - | - | - | - | 13.923 | 29.717 | 31.595 | 42.953 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 53.200 | 106.502 | 131.151 | 128.658 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 52.529 | 105.140 | 129.523 | 123.509 |
| Employees | - | - | - | - | - | - | 1 | 1 | 1 | 2 |
Check the financial reports for the company - Optirad Med S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | - | 59.816 | 109.466 | 154.970 | 266.636 |
| Inventories | - | - | - | - | - | - | 2.859 | 4.310 | 3.392 | 2.537 |
| Receivables | - | - | - | - | - | - | 4.785 | 5.145 | 86.635 | 0 |
| Cash | - | - | - | - | - | - | 52.172 | 100.010 | 64.943 | 264.099 |
| Shareholders Funds | - | - | - | - | - | - | 52.569 | 105.189 | 153.078 | 261.528 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 7.247 | 4.277 | 1.892 | 5.108 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Optirad Med S.r.l.